Ventavis (Iloprost, BAYQ6256)

DRUG5 trials

Sponsors

Bayer

Conditions

Hypertension, PulmonaryPrimary HypertensionPulmonary Arterial Hypertension

Phase 2

Aerosolized Randomized Iloprost Study II (AIR - II) Long-Term Safety, Tolerability, and Clinical Effects of Iloprost Inhalation in Patients With Primary or Secondary Pulmonary Hypertension

CompletedNCT00414687

BayerHypertension, Pulmonary

Start: 1998-07-31End: 2001-05-31Updated: 2009-05-15

Phase 3

Safety Follow-up Study of Inhaled Iloprost in Patients With Pulmonary Hypertension

CompletedNCT00185315

BayerHypertension, Pulmonary

Start: 2000-02-29End: 2005-08-31Updated: 2010-04-20

Unknown Phase

Post-Marketing Surveillance of Ventavis® in Chinese Patients With Primary Pulmonary Hypertension (PPH)

CompletedNCT00882947

BayerPrimary Hypertension

Start: 2006-02-28End: 2008-09-30Updated: 2009-04-17

Observational Description of Compliance for the Daily Ventavis Use Via the Insight Program in Class III Pulmonary Arterial Hypertension Patients

CompletedNCT01781052

BayerPulmonary Arterial Hypertension

Start: 2013-09-11End: 2017-01-16Updated: 2017-12-04

Non-interventional, Postauthorization Safety Study of Ventavis for Pulmonary Arterial Hypertension (PAH)

CompletedNCT02825160

BayerHypertension, Pulmonary

Start: 2016-08-01End: 2023-09-27Updated: 2024-08-19